Our Tests

We look beyond DNA to see cancer with new clarity.

At Bluestar Genomics, our focus is on delivering early detection data for clinicians and their patients who have a high risk of developing high-mortality cancers. We take a multi-pronged approach to early detection and are developing both single-disease and targeted multi-cancer panels of high clinical value. With the current focus on pancreatic cancer, our R&D efforts span across multiple additional cancer types, including ovarian – another high-mortality cancer type due to late detection.
Bluestar Genomics is currently concentrating on cancers with high mortality rates for which there are no or very limited screening options and cancers that often go undiagnosed until late stage, thus limiting patients’ treatment options.

Our first product is a test that detects a pancreatic cancer signal in its earliest stages by measuring levels of the biomarker 5-hydroxymethylcytosine using a simple blood draw. Pancreatic cancer is one of the deadliest forms of the disease, because it is often diagnosed too late for patients to receive effective treatment.

We are also developing targeted multi-cancer test panels to detect several different cancers through a single blood draw.

Tracking Epigenomic Signals To Detect Cancer Early